Glioma, Malignant Clinical Trial
Official title:
Clinical Study on the Effect of Neoantigens on the Therapeutic Efficacy and Intestinal Microbiota in Patients With Newly Diagnosed Glioma
The primary objective of this study is to assess the safety and tolerability, feasibility of the NeoPep Vaccine in newly diagnosed glioblastoma (GB) patients.
Status | Recruiting |
Enrollment | 10 |
Est. completion date | August 12, 2025 |
Est. primary completion date | February 12, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Ability of subject to understand and the willingness to sign written informed consent for study participation; 2. Patients with newly diagnosed high-grade glioma confirmed by histopathological and imaging evaluation; 3. Gross total resection (as defined by less than 1 cm2 residual tumor mass on the largest perpendicular axes in post-operative scan taken within 48 h post-surgery; standard MRI conformable to the present national and international guidelines is sufficient); 4. At least 0.5 g tumor tissue freshly cryopreserved during surgery,and could provide adequate amounts of PBMC; 5. Patient is a candidate for and willing to receive standard CRT with TMZ followed by maintenance TMZ cycles; 6. Age 18-70; 7. Life expectancy > 9 months; 8. KPS=70; 9. Sufficient tumor tissue samples and peripheral blood samples can be obtained for sequencing analysis, or whole exome sequencing and RNA sequencing of tumor tissue samples and peripheral blood samples have been obtained, and the sequencing data meet the prediction requirements; 10. Consent of women and men of reproductive age to use adequate and effective contraception during clinical trials; 11. Normal laboratory values for hematology, liver and renal function (serum creatinine).In detail the following values apply as inclusion criteria: 1. White blood cell count (WBC) =3.0×109/L; 2. Absolutely neutrophil count=1.0×109/L; 3. Platelet count=80×109/L; 4. Hemoglobin content=90g/L; 5. Serum creatinine=1.5 ULN or Creatinine clearance rate=40 mL/min; 6. TBil(total bilirubin)=1.5 x ULN; 7. Aspartic transaminase(AST)=2.5x ULN or Alanine aminotransferase(ALT)=2.5x ULN;Patients with liver metastases must have =5x ULN; 8. Blood coagulation function :INR=1.5x ULN;pT and APTT=1.5x ULN; 9. Urine protein< 2 +;if Urine protein=2+,24-hour urinary protein must be less than 1g. Exclusion Criteria: 1. Patients treated with immunosuppressive agents (e.g., cyclosporin CsA, tacrolimus, rapamycin, azathioprine, etc.) within the previous month; Other immunotherapy within 3 months; 2. History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 5 years unless the patient has been disease-free for 5 years; 3. Participated in other clinical trials within 30 days prior to screening; 4. Have a history of severe allergy or allergic constitution; 5. Patients who have undergone splenectomy; 6. Persons with primary or secondary immunodeficiency diseases (e.g. AIDS);Patients with autoimmune diseases; 7. Patients who received multiple oral, intramuscular, or intravenous corticosteroids within 30 days before the first dose; However, patients who received a single oral, intramuscular, or intravenous dose of dexamethasone of 5mg or less (or another hormone of equivalent potency) 14 days before the first dose were allowed; Allow inhaled corticosteroids to treat respiratory insufficiency (e.g., chronic obstructive pulmonary disease), or topical steroids; 8. Patients with uncontrollable seizures, central nervous system disorders, or psychotic loss of cognition; 9. Uncontrolled central nervous system metastases; 10. Patients had a history of chronic alcohol or drug abuse in the 6 months before screening; 11. With unstable systemic disease, such as active infection, liver cirrhosis, chronic renal failure, severe chronic pulmonary disease, unstable hypertension, unstable angina pectoris, congestive heart failure, myocardial infarction within one year, etc. ; 12. According to this procedure, the number of candidate neoantigens that can be used to make personalized vaccines is less than 20; 13. The investigator did not consider it appropriate to participate in this study. |
Country | Name | City | State |
---|---|---|---|
China | Shanghai 10th People's Hospital | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Shanghai 10th People's Hospital | Hangzhou NeoVax Biotechnology Co. LTD |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and toleration | Determine the safety and tolerability profile of NeoPep Vaccine1and 2 when administered with immunomodulators and Stupp standard treatment | Continously for about 40 weeks plus follow-up | |
Secondary | T-cell immune response | Descriptive analysis of induced T-cell immune responses after vaccinations with NeoPep Vaccine1and 2 drug products plus immunomodulators and Stupp standard treatment. | till 24 months of vaccination | |
Secondary | Overall survival(OS) | Overall survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp. | till 24 months of vaccination | |
Secondary | Progression-free survival(PFS) | Progression-free survival with NeoPep Vaccine1 and 2 plus immunomodulator in newly diagnosed glioma in patients treated with standard Stupp. | till 12 months of vaccination |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05485038 -
General Anesthesia Versus Awake Surgery in Resection of Gliomas and Metastases of Motor Areas
|
N/A | |
Recruiting |
NCT05474573 -
Concurrent Fluorescence and Sonographically Guided Eradication of Contrast-enhancing Gliomas and Metastases
|
N/A | |
Active, not recruiting |
NCT04547621 -
HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
|
Phase 1/Phase 2 | |
Recruiting |
NCT05076513 -
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
|
Early Phase 1 | |
Completed |
NCT05806619 -
Glioma: Biomolecular Aspects
|
||
Not yet recruiting |
NCT04562077 -
Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
|
||
Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
Completed |
NCT04497142 -
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
|
Phase 1/Phase 2 | |
Recruiting |
NCT05500508 -
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05656053 -
Intraoperative Rapid Diagnosis of Glioma Based on Fusion of Magnetic Resonance and Ultrasound Imaging
|
||
Recruiting |
NCT06196918 -
Efficacy and Safety of Rivaroxaban in the Prevention of Venous Thromboembolism in Glioma Patients
|
N/A | |
Recruiting |
NCT05556486 -
Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem
|
||
Recruiting |
NCT05406700 -
Niraparib In Recurrent IDH 1/2 Gliomas
|
Early Phase 1 | |
Recruiting |
NCT05773326 -
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
|
Early Phase 1 | |
Active, not recruiting |
NCT05063682 -
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
|
Phase 1 | |
Completed |
NCT05100173 -
Clinical Evaluation of Genetron IDH1 PCR Kit in Glioma Patients
|
||
Completed |
NCT05100602 -
Clinical Evaluation of Genetron TERT PCR Kit in Glioma Patients
|
||
Recruiting |
NCT05182905 -
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
|
Early Phase 1 | |
Recruiting |
NCT06381726 -
Personalized Rendering of Motor System Functional Plasticity Potential to Improve Glioma Resection and Quality of Life
|
N/A | |
Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 |